- Home
- MIRM vs SNX Comparison
MIRM vs SNX Comparison
Compare MIRM & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SNX
- Stock Information
- Founded
- MIRM 2018
- SNX 1980
- Country
- MIRM United States
- SNX United States
- Employees
- MIRM N/A
- SNX N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SNX Retail: Computer Software & Peripheral Equipment
- Sector
- MIRM Health Care
- SNX Technology
- Exchange
- MIRM Nasdaq
- SNX Nasdaq
- Market Cap
- MIRM 1.9B
- SNX N/A
- IPO Year
- MIRM 2019
- SNX 2003
- Fundamental
- Price
- MIRM $45.18
- SNX $118.18
- Analyst Decision
- MIRM Strong Buy
- SNX Strong Buy
- Analyst Count
- MIRM 11
- SNX 9
- Target Price
- MIRM $58.55
- SNX $137.22
- AVG Volume (30 Days)
- MIRM 412.6K
- SNX 789.8K
- Earning Date
- MIRM 05-07-2025
- SNX 06-24-2025
- Dividend Yield
- MIRM N/A
- SNX 1.49%
- EPS Growth
- MIRM N/A
- SNX 16.43
- EPS
- MIRM N/A
- SNX 8.00
- Revenue
- MIRM $379,251,000.00
- SNX $59,008,890,000.00
- Revenue This Year
- MIRM $29.51
- SNX $3.20
- Revenue Next Year
- MIRM $20.27
- SNX $4.26
- P/E Ratio
- MIRM N/A
- SNX $14.42
- Revenue Growth
- MIRM 69.31
- SNX 4.62
- 52 Week Low
- MIRM $23.83
- SNX $92.23
- 52 Week High
- MIRM $54.23
- SNX $145.10
- Technical
- Relative Strength Index (RSI)
- MIRM 63.46
- SNX 63.60
- Support Level
- MIRM $40.00
- SNX $112.27
- Resistance Level
- MIRM $47.43
- SNX $115.71
- Average True Range (ATR)
- MIRM 2.00
- SNX 2.42
- MACD
- MIRM 0.67
- SNX 1.77
- Stochastic Oscillator
- MIRM 88.68
- SNX 97.57
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.